Grace Therapeutics, Inc.
GRCE
$4.44
-$0.01-0.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.63M | 7.16M | 7.05M | 7.17M | 7.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.25M | 12.50M | 14.81M | 16.68M | 16.67M |
| Operating Income | -11.25M | -12.50M | -14.81M | -16.68M | -16.67M |
| Income Before Tax | -7.00M | -9.44M | -12.79M | -12.77M | -16.44M |
| Income Tax Expenses | -1.02M | -1.62M | -2.48M | -3.20M | -3.07M |
| Earnings from Continuing Operations | -5.98 | -7.82 | -10.31 | -9.57 | -13.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.98M | -7.82M | -10.31M | -9.57M | -13.37M |
| EBIT | -11.25M | -12.50M | -14.81M | -16.68M | -16.67M |
| EBITDA | -11.24M | -12.50M | -14.80M | -16.67M | -16.67M |
| EPS Basic | -0.36 | -0.59 | -0.82 | -0.85 | -1.17 |
| Normalized Basic EPS | -0.27 | -0.44 | -0.64 | -0.70 | -0.90 |
| EPS Diluted | -0.36 | -0.59 | -0.82 | -0.85 | -1.17 |
| Normalized Diluted EPS | -0.27 | -0.44 | -0.64 | -0.70 | -0.90 |
| Average Basic Shares Outstanding | 62.61M | 57.19M | 52.77M | 47.77M | 45.43M |
| Average Diluted Shares Outstanding | 62.61M | 57.19M | 52.77M | 47.77M | 45.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |